Physician profile
David E Ours
NPI 1023076882
$294.11
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.27 · 2021: $154 · 2022: $89.21 · 2023: $40.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $72.71 | 2021-2023 | |
| Abbvie INC. | $47.69 | 2021-2022 | |
| Abbott Laboratories | $36.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.59 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.06 | 2021-2022 | |
| Vistapharm, INC. | $25.96 | 2021 | |
| Pfizer INC. | $17.16 | 2021 | |
| Nabriva Therapeutics, Plc | $14.68 | 2022 | |
| Lilly USA, LLC | $13.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ours listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.